Long-term application of the aldosterone antagonist spironolactone prevents stiff endothelial cell syndrome

FASEB Journal

Volumn 27, Issue 9, 2013, Pages 3652-3659

  Drüppel, Verena ^a   Kusche Vihrog, Kristina ^a   Grossmann, Claudia ^b   Gekle, Michael ^b   Kasprzak, Bernd ^a   Brand, Eva ^a   Pavenstädt, Hermann ^a   Oberleithner, Hans ^a   Kliche, Katrin ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Atomic force microscopy; ENaC; Endothelial function; Epithelial sodium channel; Mechanical stiffness

Indexed keywords

ALDOSTERONE; EPITHELIAL SODIUM CHANNEL; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; NITRIC OXIDE; SPIRONOLACTONE;

ANIMAL CELL; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; EX VIVO STUDY; HEART PROTECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHEAR STRESS; STIFF ENDOTHELIAL CELL SYNDROME; TIME; UPREGULATION;

ATOMIC FORCE MICROSCOPY; ENAC; ENDOTHELIAL FUNCTION; EPITHELIAL SODIUM CHANNEL; MECHANICAL STIFFNESS;

ANIMALS; AORTA; CATTLE; CELLS, CULTURED; ENDOTHELIAL CELLS; EPITHELIAL SODIUM CHANNELS; HUMANS; MICROSCOPY, ATOMIC FORCE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NITRIC OXIDE; SPIRONOLACTONE; UMBILICAL VEINS;

EID: 84883394002     PISSN: None     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.13-228312     Document Type: Article

References (38)

1. Brilla, C. G., Matsubara, L. S., and Weber, K. T. (1993) Antialdosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J. Mol. Cell. Cardiol. 25, 563-575
2. Johar, S., Cave, A. C., Narayanapanicker, A., Grieve, D. J., and Shah, A. M. (2006) Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J. 20, 1546-1548
3. Benetos, A., Lacolley, P., and Safar, M. E. (1997) Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler. Thromb. Vasc. Biol. 17, 1152-1156
4. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., and Wittes, J. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709-717
5. Jessup, M., Abraham, W. T., Casey, D. E., Feldman, A. M., Francis, G. S., Ganiats, T. G., Konstam, M. A., Mancini, D. M., Rahko, P. S., Silver, M. A., Stevenson, L. W., and Yancy, C. W. (2009) 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119, 1977-2016
6. Zannad, F., Gattis, S. W., Rossignol, P., Bauersachs, J., McMurray, J. J., Swedberg, K., Struthers, A. D., Voors, A. A., Ruilope, L. M., Bakris, G. L., O'Connor, C. M., Gheorghiade, M., Mentz, R. J., Cohen-Solal, A., Maggioni, A. P., Beygui, F., Filippatos, G. S., Massy, Z. A., Pathak, A., Pina, I. L., Sabbah, H. N., Sica, D. A., Tavazzi, L., and Pitt, B. (2012) Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur. Heart J. 33, 2782-2795
7. Farquharson, C. A., and Struthers, A. D. (2000) Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101, 594-597
8. Briet, M., and Schiffrin, E. L. (2012) Vascular actions of aldosterone. J. Vasc. Res. 50, 89-99
9. Nguyen Dinh, C. A., and Jaisser, F. (2012) Extrarenal effects of aldosterone. Curr. Opin. Nephrol. Hypertens. 21, 147-156
10. Kusche-Vihrog, K., Sobczak, K., Bangel, N., Wilhelmi, M., Nechyporuk-Zloy, V., Schwab, A., Schillers, H., and Oberleithner, H. (2008) Aldosterone and amiloride alter ENaC abundance in vascular endothelium. Pflügers Arch. 455, 849-857
11. Oberleithner, H., Callies, C., Kusche-Vihrog, K., Schillers, H., Shahin, V., Riethmuller, C., MacGregor, G. A., and de Wardener, H. E. (2009) Potassium softens vascular endothelium and increases nitric oxide release. Proc. Natl. Acad. Sci. U. S. A. 106, 2829-2834
12. Fels, J., Callies, C., Kusche-Vihrog, K., and Oberleithner, H. (2010) Nitric oxide release follows endothelial nanomechanics and not vice versa. Pflügers Arch. 460, 915-923
13. Kelm, M., Feelisch, M., Deussen, A., Strauer, B. E., and Schrader, J. (1991) Release of endothelium derived nitric oxide in relation to pressure and flow. Cardiovasc. Res. 25, 831-836
14. Kliche, K., Jeggle, P., Pavenstadt, H., and Oberleithner, H. (2011) Role of cellular mechanics in the function and life span of vascular endothelium. Pflügers Arch.
15. Oberleithner, H., Riethmuller, C., Schillers, H., MacGregor, G. A., de Wardener, H. E., and Hausberg, M. (2007) Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc. Natl. Acad. Sci. U. S. A. 104, 16281-16286
16. Kusche-Vihrog, K., Urbanova, K., Blanque, A., Wilhelmi, M., Schillers, H., Kliche, K., Pavenstadt, H., Brand, E., and Oberleithner, H. (2011) C-reactive protein makes human endothelium stiff and tight. Hypertension 57, 231-237
17. Lang, F. (2011) Stiff endothelial cell syndrome in vascular inflammation and mineralocorticoid excess. Hypertension 57, 146-147
18. Hillebrand, U., Hausberg, M., Stock, C., Shahin, V., Nikova, D., Riethmuller, C., Kliche, K., Ludwig, T., Schillers, H., Schneider, S. W., and Oberleithner, H. (2006) 17beta-estradiol increases volume, apical surface and elasticity of human endothelium mediated by Na/H exchange. Cardiovasc. Res. 69, 916-924
19. Pitt, B., Williams, G., Remme, W., Martinez, F., Lopez-Sendon, J., Zannad, F., Neaton, J., Roniker, B., Hurley, S., Burns, D., Bittman, R., and Kleiman, J. (2001) The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc. Drugs Ther. 15, 79-87
20. Williams, T. A., Verhovez, A., Milan, A., Veglio, F., and Mulatero, P. (2006) Protective effect of spironolactone on endothelial cell apoptosis. Endocrinology 147, 2496-2505
21. Sato, I., Morita, I., Kaji, K., Ikeda, M., Nagao, M., and Murota, S. (1993) Reduction of nitric oxide producing activity associated with in vitro aging in cultured human umbilical vein endothelial cell. Biochem. Biophys. Res. Commun. 195, 1070-1076
22. Maciag, T., Hoover, G. A., Stemerman, M. B., and Weinstein, R. (1981) Serial propagation of human endothelial cells in vitro. J. Cell Biol. 91, 420-426
23. De Magalhaes, J. P. (2012) Programmatic features of aging originating in development: aging mechanisms beyond molecular damage? FASEB J. 26, 4821-4826
24. Ziera, T., Irlbacher, H., Fromm, A., Latouche, C., Krug, S. M., Fromm, M., Jaisser, F., and Borden, S. A. (2009) Cnksr3 is a direct mineralocorticoid receptor target gene and plays a key role in the regulation of the epithelial sodium channel. FASEB J. 23, 3936-3946
25. Kasas, S., Wang, X., Hirling, H., Marsault, R., Huni, B., Yersin, A., Regazzi, R., Grenningloh, G., Riederer, B., Forro, L., Dietler, G., and Catsicas, S. (2005) Superficial and deep changes of cellular mechanical properties following cytoskeleton disassembly. Cell Motil. Cytoskeleton 62, 124-132
26. Mazzochi, C., Bubien, J. K., Smith, P. R., and Benos, D. J. (2006) The carboxyl terminus of the alpha-subunit of the amiloridesensitive epithelial sodium channel binds to F-actin. J. Biol. Chem. 281, 6528-6538
27. Oberleithner, H., Kusche-Vihrog, K., and Schillers, H. (2010) Endothelial cells as vascular salt sensors. Kidney Int. 77, 490-494
28. Takeda, M., Tatsumi, T., Matsunaga, S., Hayashi, H., Kimata, M., Honsho, S., Nishikawa, S., Mano, A., Shiraishi, J., Yamada, H., Takahashi, T., Matoba, S., Kobara, M., and Matsubara, H. (2007) Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts. Hypertens. Res. 30, 427-437
29. Loufrani, L., and Henrion, D. (2008) Role of the cytoskeleton in flow (shear stress)-induced dilation and remodeling in resistance arteries. Med. Biol. Eng. Comput. 46, 451-460
30. Perez, F. R., Venegas, F., Gonzalez, M., Andres, S., Vallejos, C., Riquelme, G., Sierralta, J., and Michea, L. (2009) Endothelial epithelial sodium channel inhibition activates endothelial nitric oxide synthase via phosphoinositide 3-kinase/Akt in smalldiameter mesenteric arteries. Hypertension 53, 1000-1007
31. Su, Y., Edwards-Bennett, S., Bubb, M. R., and Block, E. R. (2003) Regulation of endothelial nitric oxide synthase by the actin cytoskeleton. Am. J. Physiol. Cell Physiol. 284, C1542-C1549
32. Iwashima, F., Yoshimoto, T., Minami, I., Sakurada, M., Hirono, Y., and Hirata, Y. (2008) Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 149, 1009-1014
33. Barton, M. (2010) Obesity and aging: determinants of endothelial cell dysfunction and atherosclerosis. Pflügers Arch. 460, 825-837
34. Brandes, R. P., Fleming, I., and Busse, R. (2005) Endothelial aging. Cardiovasc. Res. 66, 286-294
35. Soucy, K. G., Ryoo, S., Benjo, A., Lim, H. K., Gupta, G., Sohi, J. S., Elser, J., Aon, M. A., Nyhan, D., Shoukas, A. A., and Berkowitz, D. E. (2006) Impaired shear stress-induced nitric oxide production through decreased NOS phosphorylation contributes to age-related vascular stiffness. J. Appl. Physiol. 101, 1751-1759
36. Stokes, G. S. (2009) Management of hypertension in the elderly patient. Clin. Interv. Aging 4, 379-389
37. Lacolley, P., Safar, M. E., Lucet, B., Ledudal, K., Labat, C., and Benetos, A. (2001) Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J. Am. Coll. Cardiol. 37, 662-667
38. Krug, A. W., Allenhofer, L., Monticone, R., Spinetti, G., Gekle, M., Wang, M., and Lakatta, E. G. (2010) Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signalregulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways. Hypertension 55, 1476-1483